retatrutide update october 2025 is the most significant weight-loss pharmaceutical currently in clinical development. Phase 3 TRIUMPH-4 trial results (published December 2025) showed average body weight reduction of 28.7% at 68 weeks — approaching outcomes Retatrutide (Eli Lilly's triple GLP-1/GIP/Glucagon

At 1mg per vial, each unit provides approximately 100 research doses at a standard 10mcg dose

The higher dose amplifies appetite suppression significantly

In addition, S-adenosylhomocysteine hydrolase activity is markedly inhibited by 2-deoxyadenosine resulting in accumulation of S-adenosylhomocysteine which in turn results in reduced synthesis of S-adenosylmethionine (AdoMet), a critical substrate in transmethylation reactions

The low genetic alteration frequency found across all cancer types resulted in a small sample size, limiting our ability to study the prognostic implications of genetic alterations in different cancers